Ozempic is a branded semaglutide injection originally approved for type 2 diabetes and widely prescribed off-label for weight management. It works by mimicking the GLP-1 hormone, reducing appetite and slowing gastric emptying.
Book a Free Consultation
Most patients begin noticing appetite changes within the first 2-4 weeks. Significant weight loss typically becomes measurable by weeks 8-12 as the dose is titrated up.
The most common side effects are gastrointestinal nausea, vomiting, diarrhea, and constipation. These are usually temporary and manageable with dosing adjustments. Your Vitelize physician monitors and adjusts as needed.
Yes and you should. Resistance training is critical to preserving lean muscle mass during GLP-1 therapy. Your Vitelize trainer adjusts intensity around side-effect windows.
Coverage varies by plan. Ozempic is more commonly covered for type 2 diabetes than for weight loss. Your Vitelize physician’s team can help explore your insurance options.
Studies show that two-thirds of patients regain weight within a year of stopping GLP-1 therapy. This is why Vitelize emphasizes resistance training building lean muscle mass helps maintain metabolic rate long-term.
Both contain semaglutide, but Wegovy is FDA-approved specifically for weight management at a higher dose (2.4mg vs 1.0mg). Your physician will determine which is appropriate for you.
Ozempic carries a boxed warning for thyroid C-cell tumors observed in animal studies. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Other risks include pancreatitis, gallbladder disease, hypoglycemia (when used with insulin or sulfonylureas), kidney injury, and allergic reactions. Tell your physician about all medical conditions and medications before starting treatment.
Take the 2-minute eligibility quiz. Free, no obligation.
Am I Eligible?